ARCT Arcturus Therapeutics: חובות לטווח קצר של החברה
The market dynamics of Arcturus Therapeutics (ARCT) securities highlight cash flow instability due to grant dependency, with the indicator standing at 0.00. The business relies on the full outsourcing of mRNA drug production and testing, focusing exclusively on research. A strong patent portfolio and unique developments protect Arcturus Therapeutics (ARCT) from price wars, shifting the competition toward scientific efficacy.
פילוחי מדדים ואנליטיקה של חברת Arcturus Corp (ARCT)
Assessing stock reliability requires an analysis of the issuer's liquidity and debt load. This indicator captures the total liabilities with a maturity of up to one year. For Arcturus Therapeutics (ARCT) and its LUNAR mRNA platform, controlling these payments is critical when financing R&D. A reduction in debt confirms financial recovery, whereas an excessive minimum may signal a credit limit. The dynamics of short-term loan capital volume determine the stability of the business model.